JAK2 and myeloproliferative neoplasm: Several studies using genetic screens against JAK2 enzymatic inhibitors in MPN cell lines proposed a spectrum of secondary mutations, however, such mutations have not been reported in MPN patients yet (Deshpande et al., 2012; Kesarwani et al., 2015).